Clinical Trial Update: Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing Onvansertib in combination with nanoliposomal irinotecan, leucovorin, and fluorouracil for second-line metastatic pancreatic ductal ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• FLUOROURACIL (Fluorouracil)
• Leucovorin (folinic acid)
• Nanoliposomal irinotecan (irinotecan liposomal)
• Onvansertib (onvansertib)

Snippet

Sponsor: Cardiff Oncology | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED